Intercept Pharmaceuticals — Investor Day (December 2015)
92 slides from Intercept Pharmaceuticals's investor day presentation, Dec 1, 2015
Slide 1: 2015 Commercial Day
1 2015 Commercial Day December 1, 2015 Send questions to: investors@interceptpharma.com
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . These "forward - looking statements" are based on management's current expectations of future events and are subject to a number of important
Slide 3: Welcome & Introduction
3 Welcome & Introduction Mark Pruzanski , M.D. Chief Executive Officer, Intercept Pharmaceuticals
Slide 4: Building a Specialty Focused Business in Chronic Non-Viral Liver Diseases
4 Building a Specialty Focused Business in Chronic Non - Viral Liver Diseases with High Unmet Medical Need 4 Novel Therapeutic Approach in Underserved Diseases OCA is a farnesoid X receptor (FXR) agonist Worldwide rights (outside of Japan, China and Korea) Patent terms projected to expire at v
Slide 5: Introduction
5 Introduction Lisa Bright Chief Commercial and Corporate Affairs Officer, Intercept Pharmaceuticals
Slide 6: Establishing Intercept
6 Establishing Intercept We are Intercept. A liver health company. Our people* rejuvenate the approach to extending life for people with underserved, chronic, non - viral liver diseases. We imagine, create and deliver vital medicines that restore hope . We want to be a trusted partner to physicians
Slide 7: Driving Change in Partnership with the PBC Community
7 Driving Change in Partnership with the PBC Community Endorsed by AASLD and EASL “From ‘cirrhosis’ to ‘cholangitis’ — the change has critical implications for patients. It removes the stigmata of cirrhosis and its implications of alcohol abuse. It removes the stigmata of a poor prognosis. Its remov
Slide 8: Preparing for Our First Launch of OCA in PBC in 2016
8 Preparing for Our F irst L aunch of OCA in PBC in 2016 8 Our organization is aligned behind 5 key strategic imperatives Structuring for success Further establishing Intercept as a credible partner Enhancing the understanding of and care for PBC from a medical perspective Market Access at an optima
Slide 9: Preparing for Our First Launch of OCA in PBC in 2016
9 Preparing for Our F irst L aunch of OCA in PBC in 2016 9 Develop an understanding of the market to inform strategy and forecasting Establishing a first class commercial and medical affairs team Continuing launch preparedness – Anticipated to be on track for approval US and EU market research 80% h
Slide 10: Agenda
10 Time Topic Presenter 8:00 – 8:30 a.m. Registration 8:30 – 8:35 a.m. Welcome Dr. Mark Pruzanski, M.D. CEO, Intercept Pharmaceuticals 8:35 – 8:45 a.m. Introduction Lisa Bright Chief Commercial & Corporate Affairs Officer, Intercept Pharmaceuticals PBC Disease Background & Unmet Need 8:45 – 9:00 a.m
Slide 11: Primary Biliary Cholangitis: Disease Background and Standard of Care
11 Primary Biliary Cholangitis: Disease Background and Standard of Care Juan Carlos Lopez - Talavera , M.D. Ph.D. Senior Vice President of Medical Affairs, Intercept Pharmaceuticals
Slide 12: Historical Perspective
12 Historical Perspective ▪ 1851 - Addison and Gull are first to describe prolonged obstructive jaundice with patent bile ducts ▪ 1949 - Dauphinee and Sinclair coin the term “primary biliary cirrhosis” (PBC) ▪ 1959 - Sheila Sherlock portrays 42 cases of PBC that she personally followed, which are in
Slide 13: PBC Background
13 PBC Background 13 Background ▪ PBC is a rare autoimmune cholestatic liver disease ▪ Commonly a disease of women (10:1): 13.5 in 100,000 adults ▪ Characterized by destruction of the interlobular and septal bile ducts that may lead to cirrhosis Normal bile ducts Inflammation and scar tissue destroy
Slide 14: Alkaline Phosphatase is a Key Prognostic Marker in PBC
14 Cholestasis (toxic bile acid accumulation) Hepatocellular damage Inflammation Fibrosis Cirrhosis Healthy Liver Serum ALP Clinical use as diagnostic/prognostic AST, ALT, GGT Bilirubin Albumin, platelets Cirrhotic Liver • An increase in Alkaline Phosphatase (ALP) is observed early in the dise
Slide 15: Primary Biliary Cholangitis is a Chronic, Progressive, Autoimmune Disease
15 AMA + • Loss of tolerance to PDC - E2 Elevated ALP • Immune - mediated cholangitis Cholestasis • Ductopenia Portal Hypertension • Fibrosis • Cirrhosis Variceal Bleeding Liver - related Death/Liver Transplantation Primary Biliary Cholangitis is a Chronic , Progressive , Autoimmune D isease Impaire
Slide 16: Primary Biliary Cholangitis: Diagnosis
16 Primary Biliary Cholangitis: Diagnosis
Slide 17: Clinical Features
17 Clinical Features ▪ Clinical features vary greatly between patients : asymptomatic & slowly progressive to symptomatic & rapidly evolving ▪ Fatigue is most common symptom – Present in ~ 80% of patients – > 40% report moderate - to - severe symptoms – Mechanism unknown – Typically characterized as
Slide 18: Diagnosis
18 Diagnosis ▪ Patient must have two of the following: 1. ALP > 1.5 times ULN for more than 24 weeks 2. Serum Antimitochondrial Ab ( AMA ) > 1:4 • Serum AMA highly sensitive & specific for PBC • Detected in nearly 95% of patients - specificity ~ 100% Liver biopsy findings 3. Liver biopsy findings: •
Slide 19: Primary Biliary Cholangitis: Standard of Care
19 Primary Biliary Cholangitis: Standard of Care
Slide 20: Treatment - Ursodeoxycholic Acid (UDCA): Only FDA approved therapy
20 Treatment - Ursodeoxycholic Acid (UDCA): Only FDA approved t herapy 20 ▪ Current standard of care for PBC – 85% of diagnosed patients treated with UDCA • Dose of 13 - 15 mg/kg/day (Divided 2 - 4 times/day) ▪ UDCA is a bile acid (BA) that is present in human bile (3%) – Most hydrophilic least toxi
Slide 21: Current Therapy: Ursodeoxycholic Acid
21 Current T herapy: Ursodeoxycholic Acid ▪ Improves alkaline phosphatase & serum bilirubin ▪ Delays the progression of fibrosis and histological stage ▪ Increases liver transplant - free survival and overall survival Poupon RE, et al. Gastroenterology . 1997;113:884 - 890. European Association for
Slide 22: Biochemical Criteria Defining Response are Inconsistent
22 Currently Biochemical Criteria Defining Response are Inconsistent 1 Pares. Gastroenterology 2006, 2 Corpechot. Hepatology 2008, 3 Kuiper. Gastroenterology 2009, 4 Kumagi. Am J Gastro 2010, 5 Corpechot. Journal of Hepatology 2011, Criteria: Adequate r esponse defined as: Evaluation: Barcelona 1 AL
Slide 23: AASLD '09 and EASL '09 Treatment Guidelines
23 AASLD ‘09 and EASL ‘09 Treatment Guidelines • “A good biochemical response after one year of UDCA treatment is currently defined by a serum bilirubin 61 mg/dL (17 lmol/L), AP 63 ULN and AST 62 ULN (‘‘Paris criteria”) or by a decrease of 40% or normalization of serum AP (‘‘Barcelona criteria”). ”
Slide 24: Ongoing Unmet Medical Need in PBC
24 Treatment - Ongoing Unmet Medical Need in PBC ▪ UDCA – Only approved therapy for PBC – ~25 - 50 % of patients have an inadequate response (although definition of inadequate response varies) 37 Internal Use Only; Not for Distribution Trivedi et al. Hepatology 2015, Kumagi et al. Am J Gastroenterol
Slide 25: ALP and Bilirubin Strongly Correlated with Increased Risk of Transplant or Death
25 Alkaline phosphatase (ALP) and Bilirubin Strongly Correlated with Increased Risk of Transplant or Liver - related Death in PBC 25 Global PBC Study : – 15 North American and European centers with ~6,200 patients’ outcomes data ; ongoing • Patients on SOC as it currently exists – Alkaline phosphata
Slide 26: Key Points: PBC Overview
26 Key Points: PBC Overview ▪ PBC is a chronic, rare autoimmune, cholestatic liver disease ▪ Disproportionately affect middle - aged women ▪ Multi - factorial etiology – genetic and environmental triggers ▪ AMA and ALP are key biomarkers for diagnosis ▪ ALP is well accepted for monitoring disease an
Slide 27: PBC Patient Journey & Partnering with Patient Advocacy Community
27 Primary Biliary Cholangitis: Patient Journey & Partnering with Patient Advocacy Community Lisa Bright Chief Commercial and Corporate Affairs Officer, Intercept Pharmaceuticals
Slide 28: Our PBC Patients Are...
28 Our PBC Patients Are… 28 ▪ 85% female ▪ On average ~50 - 60 years of age ▪ 30 - 40% struggle with fatigue or pruritus ▪ Present to physicians through routine care or symptoms (fatigue or itching) and eventually referred to specialist (GI or Hep ) ▪ Tend to be more knowledgeable about the disease
Slide 29: Our Patient Advocacy Focus
29 Our Patient Advocacy Focus 29 Highlight PBC patient stories Explore unmet patient needs Engage PBC leaders Highlight International PBC Day Support the community Share scientific updates Provide unique resources , info Focused on engaging physcians and patient communities early and consistently, a
Slide 30: Patient Journey Largely Similar Across US and EU
30 Patient Journey Largely S imilar A cross US and EU * LFT = liver function tests, AMA = antimitochondrial antibodies, ANA = antinuclear antibodies, ALP = alkaline phosphatase 6 – 12 months Initial LFT* Interim Repeat LFT Imaging ALP/AMA/ ANA Biopsy PBC Diagnosis Possible ER presentation ▪ PCP ▪ GI
Slide 31: ALP is Doctors' #1 Metric for Monitoring PBC
31 ALP is doctor’s #1 metric for monitoring PBC; 64% rely on it a great deal and 57% select it as the metric they rely on most 79 75 71 32 36 92 88 61 35 61 0 50 100 Experiences around ALP (%) PBC Patients Do not Fully Understand ALP Monitoring Test ALP at least once every 6 mos. Discuss ALP results
Slide 32: Stigma Associated with the Word Cirrhosis
32 91 88 66 43 34 93 87 64 66 46 0 50 100 Share of doctors and patients who believe… (%) Doctors/patients feel stigma associated with the word “cirrhosis” Talking about PBC is embarrassing - people just assume drinking or substance abuse Most people associate “ cirrhosis ” with alcoholism Patients t
Slide 33: PBC Patients May Not Understand Symptoms Are Not Associated with Progression
33 32% 68% PBC Patients May Not Understand That Symptoms Are Not Associated with Disease Progression Myth Reality / Not sure Patients believe that worsening PBC symptoms mean that a person's PBC is worsening is a… 22% 62% My PBC patients understand that worsening PBC symptoms are not an indicator of
Slide 34: Bringing Global PBC Community Leaders Together; Renaming PBC
34 34 Bringing Global PBC Community Leaders Together in 9/2014 Resulted in Renaming PBC a nd the First Pan European Patient Hub - PBC Together
Slide 35: Online Pre-Launch PBC Education in the US
35 Online Pre - Launch PBC Education in the US for Patients and Physicians 35 U.S. PBC Physician Disease Website www.rethinkpbc.com U.S. PBC Patient Disease Website www.livingwithpbc.com Physician PBC Disease Education Patient PBC Disease Education Kit
Slide 36: Intercept Practice to Policy Health Awards Program
36 Introducing the Intercept Practice to Policy Health Awards Program Open to Healthcare Organizations, Policy Groups, Patient Advocacy Groups and Academic Groups 36
Slide 37: Primary Biliary Cholangitis: Redefining Treatment Success
37 Primary Biliary Cholangitis: Redefining Treatment Success Juan Carlos Lopez - Talavera , M.D. Ph.D. Senior Vice President of Medical Affairs, Intercept Pharmaceuticals
Slide 38: Global PBC Study Group: Overview
38 Global PBC Study Group: Overview ▪ Global PBC Study Group, an international and multicenter collaboration between 15 liver centers in 8 North American and European countries ▪ Combined individual patient data from major long - term follow - up cohorts ▪ Clinical data of 6191 PBC patients 1. Lindo
Slide 39: Current Therapy: Ursodeoxycholic Acid
39 Current Therapy: Ursodeoxycholic Acid Current Management Paradigm ▪ Bile acid therapy (UDCA) – Hydrophilic bile acid, dilutes toxic endogenous bile acids – Goal is to break cycle of cholestatic injury For some patients: ▪ Improves serum bilirubin ▪ Delays the progression of fibrosis and histologi
Slide 40: ALP and Bilirubin Strongly Correlate with Outcomes
40 ALP and Bilirubin Strongly Correlate with Outcomes Lammers, WJ et al. Gastroenterology. 2014 Dec;147(6):1338 - 1349.e5. doi: 10.1053/j.gastro.2014.08.029.
Slide 41: Clinical Outcomes of Uncontrolled PBC
41 Clinical Outcomes of Uncontrolled PBC 41 1 : Kumagi et al. 2 : Trivedi 3: Lammers AASLD 2015 Histologic progression/Cirrhosis: • >80% of patients had histologic progression at ~ 10 years 1 HCC: • 12 - month biochemical non - response is associated with increased future risk of developing HCC 2 Tr
Slide 42: OCA: Investigational Drug for PBC
42 OCA: Investigational Drug for PBC
Slide 43: Bile Acids: Novel Role in Modulating Disease
43 Bile acids: role in digestion ▪ Bile acids are synthesized from cholesterol in the liver ▪ Facilitate dietary absorption of lipids and nutrients based on their natural detergent properties – Released by gallbladder into gut during digestion – Reabsorbed & conserved ( enterohepatic recirculation)
Slide 44: Obeticholic Acid is a Novel Therapeutic Option Targeting FXR
44 OH O OH HO Me Me OH O OH HO Me Me OH O OH HO Me Me OCA 6a - ethyl chenodeoxycholic acid CDCA chenodeoxycholic acid UDCA ursodeoxycholic acid FXR EC 50 (agonist) 0.09 m M No activity Pellicciari R. J.Med.Chem 2002 ~ 100x FXR agonism 8.6 m M Obeticholic Acid (OCA) is a N ovel T herapeutic O ption
Slide 45: FXR Core Mechanism of Action
45 FXR Core Mechanism of Action ▪ What is FXR? – Farnesoid X receptor (FXR) is a nuclear receptor expressed at high levels in the liver and intestine, and is the master regulator of bile acid homeostasis 1 ▪ P revents the accumulation of toxic bile acids by: 1 – Decreasing synthesis – Increasing sec
Slide 46: OCA Clinical Development in PBC
46 Trial Description Duration N= Dose Status Phase 2 201 OCA 12 weeks 59 10mg or 50mg Completed : m et primary and secondary endpoints 202 UDCA + OCA 12 weeks 165 10mg, 25mg or 50mg Completed: m et primary and secondary endpoints Phase 3 POISE UDCA + OCA 1 year 217 5mg or 10mg DB completed: m et pri
Slide 47: POISE: Phase 3 Trial Design
47 POISE: Phase 3 Trial Design UDCA = Ursodeoxycholic acid; ALP=Alkaline phosphatase; ULN=Upper limit of normal Screening OCA 10 mg (n=73) Placebo (n=73) M3 M12 M6 W2 0 M9 If on UDCA : Continue UDCA OCA 5 mg OCA Titration at 6 Months: Patients in OCA titration arm titrated from 5 mg to 10 mg at Mont
Slide 48: OCA Met the Primary Endpoint of Phase 3 POISE Trial
48 48 OCA Met the Primary Endpoint of Phase 3 POISE Trial 10% 47% 46% 0% 10% 20% 30% 40% 50% Placebo* OCA 10mg* OCA 5-10mg* EFFICACY: Primary endpoint: ALP < 1.67x ULN (with ≥ 15% reduction) & normal bilirubin at 12 months OCA met the primary endpoint at every time point assessed during the tria
Slide 49: Some UDCA/Placebo Patients Experienced ALP Elevation in POISE at 12 Months
49 Some UDCA/placebo P atients Experienced ALP E levation in POISE at 12 Months ~35% of placebo/UDCA patients experienced increases in ALP at month 12 in POISE study 49
Slide 50: 98% of PBC Patients on OCA 10mg Improved or Stabilized ALP
50 98% of PBC patients on OCA 10mg (added to UDCA) improved or at least stabilized ALP over 12 months ~35% of placebo/UDCA patients experienced increases in ALP at month 12 in POISE study Some UDCA/placebo P atients Experienced ALP E levation in POISE at 12 Months
Slide 51: PBC: 2015 AASLD Rundown
51 PBC: 2015 AASLD Rundown
Slide 52: Important Presence at AASLD 2015
52 Important Presence at AASLD 2015 CLINICAL Abstracts/Posters/Oral: OCA/PBC (N=17) 52 Poster Sustained Improvement in the Markers of Cholestasis in an Open Label Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis Patients [301 LTSE] Trauner Poster Efficacy and Safety of Obetich
Slide 53: Market Sizing and Market Access
53 Market Sizing and Market A ccess Lisa Bright Chief Commercial and Corporate Affairs Officer, Intercept Pharmaceuticals 53
Slide 54: Global PBC Patient Waterfall
54 Global PBC Patient Waterfall 128k 115k 54k 49k 43k 29k 15k 111k 109k 47k 42k 37k 25k 13k 29k 28k 11k 10k 8k 6k 3k 291k 274k 123k 110k 97k 66k 34k Prevalence Access Diagnosed Under treater care Treated Uncontrolled (ALP > ULN) Uncontrolled (ALP > 1.67) US EU5 Canada ANZ ROE Global Prevalence / OCA
Slide 55: Stratification of PBC Patients Based on ALP
55 Stratification of PBC Patients Based on ALP 55 35% 10% 13% 13% 29% ALP AFTER 12 MONTHS ON URSO ALP ULN - 1.67x ULN ALP 1.67 - 2.0x ULN ALP > 3.0x ULN ALP > 2.0x ≤ 3.0x ULN ALP < ULN Lammers el al Gastroenterology. 2014 Dec;147(6):1338 - 1349
Slide 56: Market Research: Current Physician Treatment Approach in PBC
56 Market Research: Current Physician Treatment Approach in PBC Base: Physicians who view ALP level reductions as a marker of treatment success - EU Total n=(156) UK n=(35), France n=(31), Ger many n=(22), Italy n=(36), Spain n=(32) Note: Current wave answer options changed significantly, and theref
Slide 57: Increasing Sensitivity Around Pricing; Price OCA Based on Value
57 Increasing Sensitivity A round Pricing in the US (as well as EU) Important to Price OCA Based on Value 57 OCA is on 2016 ICER Review list
Slide 58: Price Drivers Vary By Country
58 Price Drivers Vary By Country There’s been a payor shift to demand more value in terms of patients outcomes for orphan disease products. Even where price is not negotiated we are seeing increasing willingness to impose restrictions in orphan indications Clinical effectiveness ▪ Patient - relevant
Slide 59: Research on OCA Pricing in PBC
59 Research on OCA Pricing in PBC 59 KOLs National Regional/ local USA 2 8 17 Canada 2 2 4 France 2 5 - Germany 2 3 5 Italy 2 2 6 Spain 2 2 6 UK 2 3 5 Sweden 2 2 4 Total 16 19 47 Qualitative research sample Research methodology Disease background presentation • Prior to interviews, payors received a
Slide 60: The Orphan Drug Landscape Presents Opportunities and Challenges
60 The Orphan D rug L andscape P resents C ertain O pportunities and Challenges that will be Considered as Part of OCAs Pricing Strategy 60 Opportunity ▪ If approved, OCA will be the only therapeutic option for PBC patients with inadequate response to UDCA ▪ Orphan disease, limited budget impact ▪ T
Slide 61: Developing the OCA Value Story
61 Developing the OCA Value Story 61 ALP endpoints Bilirubin endpoints Inflammatory markers Fibrosis endpoints Availability of clinical evidence in POISE 100% 0% 100% Payor confidence in OCA ALP, the key biochemical marker of disease progression in PBC was reduced or not increased in 98% of patients
Slide 62: Health Economics Modelling is Underway
62 Health Economics Modelling is U nderway 62 Structure of HE model
Slide 63: US Launch Preparedness
63 US Launch Preparedness Richard Kim Head US Commercial, Intercept Pharmaceuticals
Slide 64: Significant Progress Made For U.S. Launch Readiness
64 Significant Progress Made For U.S. Launch Readiness ▪ Key market insights gained – In 2015 alone, US Business Intelligence Team completed 12 major initiatives in preparation for launch with over 1000 hours of interviews with key customers (Patients, Physicians and Payors ) ▪ Sales team hired, tra
Slide 65: Intercept Was Front and Center at AASLD
65 Intercept Was Front and Center at AASLD • 28 presentations including 4 oral presentations • AASLD Founder’s Club for AASLD Foundation • Medical sponsored 2 symposia, PBC and NASH
Slide 66: Challenges Exist, However the Launch of OCA Provides Opportunity
66 Challenges Exist, However the Launch of OCA Provides the Opportunity to Transform PBC…and Intercept ▪ Very established customer behavior in PBC ▪ Lack of universal view on treatment success ▪ Increased scrutiny on pharma pricing ▪ Low awareness of OCA for PBC in GI community practice ▪ Perception
Slide 67: ~90% of PBC Patients in the U.S. are Under the Care of a Physician
67 ~90% Of PBC Patients in t he U.S. are Under the Care of a Physician and t he Ultimate OCA Opportunity Will Be Linked to How Treatment Success is Defined 67 46%^ 92% 88% 71% 35% 0.04% or intolerant to SOC* *3% of patients are intolerant to UCDA ^Access to healthcare assumed in calculation at 88.1%
Slide 68: Timely Patient Follow Up Will Be Critical
68 Having Timely Patient Follow Up Will Be Critical to Inform About Potential New Treatment Options * LFT = liver function tests, AMA = antimitochondrial antibodies, ANA = antinuclear antibodies, ALP = alkaline phosphatase 6 – 12 months Initial LFT* Interim Repeat LFT Imaging ALP/AMA/ ANA Biopsy PBC
Slide 69: State-level PBC Claims are Concentrated
69 State - level PBC Claims are Concentrated , 80% are in 21 States Source: PBC claims data: Intercept PBC Stakeholder Profile Analysis – Key Findings, Nov. 7, 2014 Update (IMS), Slide 41. PBC=Pri mary Biliary Cirrhosis PBC Claims: State - Level Quintile Profile 53,907 PBC claims. Excludes DGP, VET
Slide 70: Highest Prescribing PBC Treaters Concentrated in Urban Areas
70 We Know Where the Highest Prescribing PBC Treaters Are; As Expected They Are Concentrated in Urban Areas, But There Are Some in Remote Areas *Core - Based Statistical Area
Slide 71: U.S. Objectives Tightly Aligned with Global Strategic Imperatives
71 Establish Intercept as a credible partner in unmet liver diseases U.S. Objectives Tightly Aligned with Global Strategic Imperatives 71 Ensure maximum patient access at the optimal price Communicate an inspiring and compelling brand story based on FXR Structure for success Prepare to appropriately
Slide 72: Integrated Hub and Distribution Model
72 In t e g r ated Hub In t e g r ated Hub and Distribution Model Co m prehensi v e Hu b Ser v ices M aster D ata M anage m ent D ashboards w ith Data Anal y tics Specialty Phar m acy C losed/Li m ite d / O p en Net w ork Prescribe r s Patients & C aregi v ers Pa y ers M anufa c t u r er Other Ancil
Slide 73: Creating Best-in-Class Data Warehouse and Analytics
73 Creating Best - in - Class D ata W arehouse and Analytics 73 ▪ Collect, process and analyze data from CRM, Patient Services HUB, Distribution Channels and IMS ▪ Provides unique data (beside Rx and Units) to help profile and serve our physicians and patients in the best way possible ▪ For each cli
Slide 74: PBC Payor Coverage is Representative of Total Healthcare Expenditures
74 PBC Payor Coverage is Representative of Total Healthcare Expenditures 74 US National Health Expenditure, 2012 (Billions) Source: CMS. National Health Expenditure Data, 2014. Available online at http://www.cms.gov/Research - Statistics - Data - and - Systems/Statistics - Trends - and - Reports/Nat
Slide 75: Sales Force Sizing Based on Optimal Coverage of Top Quintile Physicians
75 Sales Force Sizing was Based on Optimal Coverage of Top Quintile Physicians and Will Be Adjusted Where Necessary 75 ▪ Hepatologists and gastroenterologists combined account for 72% of all patients being treated for PBC ▪ Hepatologists and gastroenterologists account for 80 - 85% of all high quint
Slide 76: Sales Team Territories Aligned to Maximize Coverage
76 The Sales Teams Territories Have Been Aligned to Maximize C overage for PBC Prescribers and Clinical Nurse Educators Will P rovide A dditional Customer Service ▪ 6 regions managed by Regional Directors (RDs) – Span of control of 7 to 8 territories per region ▪ 45 territories managed by our sales
Slide 77: On Track to Support February PDUFA Date for OCA in PBC
77 On Track to Support A February 29 th PDUFA date for OCA in PBC 77 ▪ Global trade name(s) approved for EMA and conditionally approved by FDA ▪ PBC launch campaign in late stage development and being tested with customers ▪ Promotional programs and training under development with program deployment
Slide 78: Building a Best-in-Industry Team for a Strong PBC Launch
78 We Are Building a Best - in - Industry Team and Together as ONE Team Plan to Have a Strong PBC Launch ▪ Our customers are ready for a new treatment option for PBC – We will know who to see and when to see them ▪ Preparing the scientific message platform to communicate the OCA PBC value propositio
Slide 79: Ex-US Launch Preparedness
79 Ex - US Launch Preparedness Lisa Bright Chief Commercial and Corporate Affairs Officer, Intercept Pharmaceuticals
Slide 80: Growing Our Global Presence
80 • Intercept Teams established U.S. and across Europe: UK , Ireland, Canada, Nordic Region, France, Benelux Region, Germany, Austria, Switzerland, Spain, Portugal and Italy • Build out in Australia and NZ from 2017 • EU HQ in London, Kings Cross • Focused on market access (General Managers, market
Slide 81: EUCA Launch Preparedness Well Underway
81 EUCA Launch Preparedness Well Underway ▪ EUCA regional infrastructure in place – temporary offices in all countries ▪ High caliber leadership teams recruited covering 21 countries, consistent with our vision to establish high credibility in hepatology – ≥ 80% of hires have extensive hepatology th
Slide 82: Medical Affairs
82 Medical Affairs Juan Carlos Lopez - Talavera , M.D. Ph.D. Senior Vice President of Global Medical Affairs, Intercept Pharmaceuticals
Slide 83: Medical Affairs Activities to Support a Successful PBC Launch
83 Medical Affairs Activities to Support a Successful PBC Launch 83 PBC Publication Plan Healthcare Outcomes Research Investigator Initiated Research Medical Science Liaisons Medical Communications Thought Leader Engagement
Slide 84: Medical Affairs Activities to Support a Successful PBC Launch
84 Medical Affairs Activities to Support a Successful PBC Launch 84 PBC Publication Plan Healthcare Outcomes Research Investigator Initiated Research (IIR) Medical Science Liaisons Medical Communications Thought Leader Engagement • PBC Publication Plan and process in place • ~ 20 Planned Manuscripts
Slide 85: Educating on Pruritus Management
85 Educating on Pruritus Management Overview - Medical Education Dissemination Medical Conferences • AASLD’14 (1 poster) and AASLD’15 (1 poster) • FXR Agonist Obeticholic Acid: Pruritus, A Common Side Effect Ameliorated by Dose Titration • Monitoring Pruritus in Patients with Primary Biliary Cirrhos
Slide 86: PBC Advisory Boards: 2015-1H2016 Roadmap
86 86 PBC Advisory Boards: 2015 - 1H2016 Roadmap (N=64) Obtaining Insights from Varied Audiences through Launch Global N= 2 Q3’15 Q4’15 Q1’16 Q2’16 AASLD EASL National N= 37 Regional N= 23 NP/PA N=1 Patient Advocate N=1 Global N=15 - 20 Global N=15 - 20 Regional (7) N=8 - 12 Regional (7) N=8 - 12 Na
Slide 87: US Advisory Boards Top-Line Summary
87 US Advisory Boards Top - Line Summary (N=11) 87 Lack of consensus surrounding criteria for PBC treatment Advisors manage pruritus; recommend education tools PBC monitoring and defining treatment success “Encouraged” by OCA Biochemical Data Advisors see room for improvement in current PBC treatmen
Slide 88: Conclusions
88 Conclusions Lisa Bright Chief Commercial and Corporate Affairs Officer, Intercept Pharmaceuticals
Slide 89: Conclusions
89 Conclusions ▪ Unmet need in PBC is significant ▪ Significant insights into all aspects of the disease gained over last 12 months ▪ Entire company aligned behind the 5 strategic imperatives ▪ Continuing to enhance understanding of and care for PBC ▪ Built outstanding commercial and medical affairs
Slide 90: Intercept Commercial Q&A
90 Intercept Commercial Q&A Send questions to: investors@interceptpharma.com
Slide 91: Appendix
91 Appendix
Slide 92: Project RAPID: Overview
92 Project RAPID: Overview An example of research undertaken and presented as a poster at AASLD 92 We spoke with 3 groups – doctors who treat PBC, PBC patients, and the General Public Doctors WHEN : From December 11, 2014 to January 12, 2015 SAMPLE SIZE : 322 HOW: Fieldwork was conducted online usin
Intercept Pharmaceuticals — Investor Day (December 2015) on 6ix